A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Valencia Technologies Retains PRIA Healthcare to Improve Patient Access to the eCoin for Treatment of Urge Urinary Incontinence

Valencia Technologies Corporation today announced it has retained PRIA Healthcare to assist in patient access for Valencia’s recently FDA approved proprietary product, eCoin®. eCoin is a leadless tibial nerve neurostimulator for the treatment of urge urinary incontinence (UUI), affecting over 60% of patients who suffer from Overactive Bladder (OAB).

eCoin® consists of a coin-sized neurostimulator which is implanted subcutaneously in the lower leg during a minimally invasive outpatient procedure utilizing only local anesthetic.

PRIA has 10 years of experience assisting MedTech companies improve patient access to new medical devices. PRIA assists clients and develops patient-centric prior authorization and appeals programs that leverage clinical evidence and historical coverage decisions to best inform payors about the individual patient’s story. PRIA is a relentless advocate, dedicated to helping patients avoid the pitfalls of today’s medical insurance systems, helping more patients gain access to the care most likely to benefit them.

Mr. Clay Schwabe, VP, Business Development of PRIA Healthcare Management, stated, “PRIA leverages our experience in accelerating patient access to innovative medical solutions to help put therapy decisions back in the hands of the healthcare provider. We are especially excited to work with Valencia Technologies and eCoin. Our goal is to create more opportunities for indicated patients with bladder dysfunction to access this remarkable device.”

Ms. Ann Decker, Vice President, Reimbursement and Health Policy at Valencia Technologies, states, “We are excited to partner with PRIA as they help Valencia Technologies expand its eCoin technology into the marketplace through educating the numerous U.S. insurance companies on the clinically supported benefits of eCoin. Our confidence in the PRIA Team is a direct result of their many successes assisting other MedTech companies on this same journey with their emerging technologies.”

About PRIA 
Since 2012, PRIA Healthcare has been a national leader in reimbursement and market access to the healthcare arena throughout the United States. Led by a team of industry veterans, PRIA is committed to ensuring the latest medical technologies and procedures are available to patients both during clinical trials and through product commercialization. PRIA diligently works to influence payers to establish patient access to life changing devices, therapies, treatments, and procedures by leveraging clinical data, patient, and physician rights.

Valencia Technologies Corporation is a private medical technology company located in Valencia, California. The company designed and manufactured its eCoin® device for the treatment of urge urinary incontinence (UUI).

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy